Evidence map›Paper›PMID 37079727›Full record

ArticleRheumatology (Oxford, England)2023

CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization.

Sarah Luebker, Tracy M Frech, Shervin Assassi, Brian Skaug, Jessica K Gordon, Kimberly Lakin, Elana J Bernstein, Yiming Luo, Virginia D Steen, Ami A Shah and 19 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 17 institutions in 1 country.

Sarah LuebkerDivision of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Tracy M FrechDivision of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-5472-3840
Shervin AssassiDivision of Rheumatology, Department of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Brian SkaugDivision of Rheumatology, Department of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-6689-4655
Jessica K GordonDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York City, NY, USA.
Kimberly LakinDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York City, NY, USA.
Elana J BernsteinDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID 0000-0001-5560-6390
Yiming LuoDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, New York, NY, USA.
Virginia D SteenDepartment of Medicine, Georgetown University Medical Center, Washington, DC, USA.
Ami A ShahDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Laura K HummersDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Carrie RichardsonDivision of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-2541-175X
Duncan F MooreDivision of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Dinesh KhannaDivision of Rheumatology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1412-4453
Flavia V CastelinoDivision of Rheumatology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Lorinda ChungDivision of Immunology and Rheumatology, Department of Medicine, Stanford University and Palo Alto VA Health Care System, Palo Alto, CA, USA.
Puneet KapoorDivision of Immunology and Rheumatology, Department of Medicine, Stanford University and Palo Alto VA Health Care System, Palo Alto, CA, USA.
Faye N HantDivision of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Victoria K ShanmugamDepartment of Anatomy, George Washington University, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
John M VanBurenDivision of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Jessica AlveyDivision of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Monica HardingDivision of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Ankoor ShahDivision of Rheumatology and Immunology, Department of Medicine, Duke University, Durham, NC, USA.
Ashima MakolDivision of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Dorota Lebiedz-OdrobinaDivision of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Julie K ThomasDivision of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Elizabeth R VolkmannDivision of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-3750-6569
Jerry A MolitorDivision of Rheumatic and Autoimmune Diseases, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Nora SandorfiDivision of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
University of Utah · USJohns Hopkins University · USColumbia University · USHospital for Special Surgery · USNorthwestern University · USThe University of Texas Health Science Center at Houston · USVA Palo Alto Health Care System · USVA Tennessee Valley Healthcare System · USGeorgetown University · USGeorge Washington University · USMassachusetts General Hospital · USMayo Clinic in Arizona · USMedical University of South Carolina · USUniversity of California, Los Angeles · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of Pennsylvania · US

Funding

Training Program in Adult and Pediatric RheumatologyT32AR050942 · NIAMS · STANFORD UNIVERSITY · PI LEWIS, DAVID BRAM, ROBINSON, WILLIAM H · 2005 to 2025
$6.6M
Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung DiseaseR01HL164758 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Elana J. Bernstein · 2022 to 2026
$3.5M
Identifying predictors of treatment response in systemic sclerosis-related interstitial lung diseaseK23HL150237 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOLKMANN, ELIZABETH R · 2020 to 2024
$910k
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in sclerodermaK24AR080217 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Ami Aalok Shah · 2022 to 2026
$847k
Pathogenic effects of the DNASE1L3 R206C variant in systemic sclerosisK08AR081402 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Brian Skaug · 2022 to 2026
$821k
Screening Chest CT to Detect Interstitial Lung Disease in Systemic SclerosisK23AR075112 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, ELANA · 2019 to 2023
$794k
CSRD VA I01 CX002111NHLBI NIH HHS K23 HL150237NHLBI NIH HHS R01 HL164758NIAMS NIH HHS K08 AR081402NIAMS NIH HHS K23 AR075112NIAMS NIH HHS K24 AR080217NIAMS NIH HHS T32 AR050942
6 · The paper itself

Abstract

objectivesSSc is associated with increased health-care resource utilization and economic burden. The Collaborative National Quality and Efficacy Registry (CONQUER) is a US-based collaborative that collects longitudinal follow-up data on SSc patients with <5 years of disease duration enrolled at scleroderma centres in the USA. The objective of this study was to investigate the relationship between gastrointestinal tract symptoms and self-reported resource utilization in CONQUER participants.

methodsCONQUER participants who had completed a baseline and 12-month Gastrointestinal Tract Questionnaire (GIT 2.0) and a Resource Utilization Questionnaire (RUQ) were included in this analysis. Patients were categorized by total GIT 2.0 severity: none-to-mild (0-0.49); moderate (0.50-1.00), and severe-to-very severe (1.01-3.00). Clinical features and medication exposures were examined in each of these categories. The 12-month RUQ responses were summarized by GIT 2.0 score categories at 12 months.

resultsAmong the 211 CONQUER participants who met the inclusion criteria, most (64%) had mild GIT symptoms, 26% had moderate symptoms, and 10% severe GIT symptoms at 12 months. The categorization of GIT total severity score by RUQ showed that more upper endoscopy procedures and inpatient hospitalization occurred in the CONQUER participants with severe GIT symptoms. These patients with severe GIT symptoms also reported the use of more adaptive equipment.

conclusionThis report from the CONQUER cohort suggests that severe GIT symptoms result in more resource utilization. It is especially important to understand resource utilization in early disease cohorts when disease activity, rather than damage, primarily contributes to health-related costs of SSc.

Indexed as

Gastrointestinal DiseasesScleroderma, SystemicHumansRegistriesSelf ReportSurveys and Questionnairesgastrointestinal tracthealth outcomeshealth statusSSc

Identifiers

PMID37079727
PMCPMC10547507
OpenAlexW4366466006

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.